(Q51862639)

14 April 2018

title

A Bayesian analysis of bisphosphonate effects and cost-effectiveness in post-menopausal osteoporosis. (English)

1 reference

14 April 2018

0 references

I Aursnes Md

1

1 reference

14 April 2018

G Storvik Phd

series ordinal

2

1 reference

14 April 2018

J Gåsemyr Phd

series ordinal

3

1 reference

14 April 2018

B Natvig Phd

series ordinal

4

1 reference

14 April 2018

publication date

1 November 2000

1 reference

14 April 2018

Pharmacoepidemiology and Drug Safety

published in

1 reference

14 April 2018

volume

9

1 reference

14 April 2018

issue

6

1 reference

14 April 2018

page(s)

501-509

1 reference

14 April 2018

Bisphosphonates act on rat bone resorption through the mediation of osteoblasts

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1099-1557%28200011%299%3A6%3C501%3A%3AAID-PDS534%3E3.0.CO%3B2-O

Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1557%28200011%299%3A6%3C501%3A%3AAID-PDS534%3E3.0.CO%3B2-O

The statistical basis of public policy: a paradigm shift is overdue

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1557%28200011%299%3A6%3C501%3A%3AAID-PDS534%3E3.0.CO%3B2-O

Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1557%28200011%299%3A6%3C501%3A%3AAID-PDS534%3E3.0.CO%3B2-O

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1557%28200011%299%3A6%3C501%3A%3AAID-PDS534%3E3.0.CO%3B2-O

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1557%28200011%299%3A6%3C501%3A%3AAID-PDS534%3E3.0.CO%3B2-O

Predicting various fragility fractures in women by forearm bone densitometry: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1557%28200011%299%3A6%3C501%3A%3AAID-PDS534%3E3.0.CO%3B2-O

Events per person year--a dubious concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1557%28200011%299%3A6%3C501%3A%3AAID-PDS534%3E3.0.CO%3B2-O

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1557%28200011%299%3A6%3C501%3A%3AAID-PDS534%3E3.0.CO%3B2-O

Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1557%28200011%299%3A6%3C501%3A%3AAID-PDS534%3E3.0.CO%3B2-O

10.1002/1099-1557(200011)9:6<501::AID-PDS534>3.0.CO;2-O

21 January 2018

Identifiers

DOI

0 references

1 reference

14 April 2018